Epigenetics of Cutaneous T-Cell Lymphomas

Area of Science:

• Oncology
• Epigenetics
• Dermatology

Background:

• Epigenetic modifications rarely act alone, often forming networks that regulate cellular processes.
• Cutaneous malignancies are influenced by epigenetic alterations, yet knowledge of these changes in cutaneous lymphomas is limited.
• This review specifically addresses epigenetic modifications in cutaneous T-cell lymphomas (CTCL), including mycosis fungoides, Sézary syndrome, and anaplastic large cell lymphoma.

Purpose of the Study:

• To review and summarize epigenetic changes in CTCL.
• To discuss epigenetic modifications, including DNA methylation and histone acetylation/methylation.
• To explore epigenetic-targeted therapies for CTCL.

Main Methods:

• Literature review focusing on epigenetic modifications in CTCL.
• Categorization of epigenetic changes into DNA methylation and histone modifications.
• Summary of drug characteristics and current research on epigenetic-targeted therapies.

Main Results:

• Epigenetic changes in CTCL involve DNA methylation and histone modifications.
• Current epigenetic-targeted therapies, such as histone deacetylase inhibitors, show variable efficacy in CTCL.
• Epigenetic modifications and drug characteristics relevant to CTCL treatment are detailed.

Conclusions:

• Epigenetic modifications play a significant role in the pathogenesis of CTCL.
• Epigenetic-targeted combination therapy presents a promising strategy to overcome limitations of current treatments.
• Further research into epigenetic-targeted therapies could improve outcomes for CTCL patients.